MétaCan
Menu
Back to cohort

Parameter Space and Potential for Biomarker Development in 25 Years of fMRI Drug Cue Reactivity

2024· review· en· W4391598248 on OpenAlex
Arshiya Sangchooli, Mehran Zare-Bidoky, Ali Fathi Jouzdani, Joseph P. Schacht, James M. Bjork, Eric D. Claus, James J. Prisciandaro, Stephen J. Wilson, Torsten Wüstenberg, Stéphane Potvin, Pooria Ahmadi, Patrick Bach, Alex Baldacchino, Anne Beck, Kathleen T. Brady, Judson A. Brewer, Anna Rose Childress, Kelly E. Courtney, Mohsen Ebrahimi, Francesca M. Filbey, Hugh Garavan, Dara G. Ghahremani, Rita Z. Goldstein, Erica N. Grodin, Colleen A. Hanlon, Amelie Haugg, Markus Heilig, Andreas Heinz, Adrienn Holczer, Ruth J. van Holst, Jane E. Joseph, Anthony Juliano, Marc J. Kaufman, Falk Kiefer, Arash Khojasteh Zonoozi, Rayus Kuplicki, Marco Leyton, Edythe D. London, Scott Mackey, F. Joseph McClernon, William Mellick, Kirsten C. Morley, Hamid R. Noori, Mohammad Ali Oghabian, Jason A. Oliver, Max M. Owens, Martin P. Paulus, Irene Perini, Parnian Rafei, Lara A. Ray, Rajita Sinha, Michael N. Smolka, Ghazaleh Soleimani, Rainer Spanagel, Vaughn R. Steele, Susan F. Tapert, Sabine Vollstädt‐Klein, Reagan R. Wetherill, Katie Witkiewitz, Kai Yuan, Xiaochu Zhang, Antonio Verdejo‐García, Marc N. Potenza, Amy C. Janes, Hedy Kober, Anna Zilverstand, Hamed Ekhtiari

Why this work is in the frame

A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.

affAt least one author lists a Canadian institution in the pinned OpenAlex snapshot.
fundA Canadian funder is recorded on the work.

Bibliographic record

VenueJAMA Psychiatry · 2024
Typereview
Languageen
FieldNeuroscience
TopicNeurotransmitter Receptor Influence on Behavior
Canadian institutionsMcGill UniversityUniversity of British ColumbiaUniversité de Montréal
FundersUniversity of Colorado School of Medicine, Anschutz Medical CampusNational Center for Complementary and Alternative MedicineNational Center for Complementary and Integrative HealthNational Institute on AgingNational Institute on Alcohol Abuse and AlcoholismFaculty of Medicine and Health, University of SydneyNational Cancer InstituteMelbourne School of Psychological SciencesDepartment of Psychiatry, Faculty of Medicine, University of British ColumbiaLaureate Institute for Brain Research, University of TulsaPerelman School of Medicine, University of PennsylvaniaSydney Medical SchoolUniversity of California, San DiegoNational Institutes of HealthMcGovern Institute for Brain Research, Massachusetts Institute of TechnologyWake Forest School of MedicineUniversité de MontréalNational Institute of Diabetes and Digestive and Kidney DiseasesUniversitätsspital ZürichUniversiteit van AmsterdamMcGill UniversityDeutsche ForschungsgemeinschaftMcLean HospitalAmsterdam NeuroscienceLinköpings UniversitetNational Institute of Mental HealthUniversity of St AndrewsBrown UniversityVirginia Commonwealth UniversityAmsterdam University Medical CentersUniversity of California, Los AngelesUniversity of MinnesotaTehran University of Medical Sciences and Health ServicesUniversity of South CarolinaUniversität ZürichNational Institute on Drug AbuseUniversity of PennsylvaniaSzegedi TudományegyetemBrainsWayMassachusetts Institute of TechnologyPennsylvania State University
KeywordsBiomarkerMedicineDrug developmentMEDLINEClinical study designImaging biomarkerAddictionClinical trialPsychologyMagnetic resonance imagingPsychiatryInternal medicineDrug

Abstract

fetched live from OpenAlex

Importance: In the last 25 years, functional magnetic resonance imaging drug cue reactivity (FDCR) studies have characterized some core aspects in the neurobiology of drug addiction. However, no FDCR-derived biomarkers have been approved for treatment development or clinical adoption. Traversing this translational gap requires a systematic assessment of the FDCR literature evidence, its heterogeneity, and an evaluation of possible clinical uses of FDCR-derived biomarkers. Objective: To summarize the state of the field of FDCR, assess their potential for biomarker development, and outline a clear process for biomarker qualification to guide future research and validation efforts. Evidence Review: The PubMed and Medline databases were searched for every original FDCR investigation published from database inception until December 2022. Collected data covered study design, participant characteristics, FDCR task design, and whether each study provided evidence that might potentially help develop susceptibility, diagnostic, response, prognostic, predictive, or severity biomarkers for 1 or more addictive disorders. Findings: There were 415 FDCR studies published between 1998 and 2022. Most focused on nicotine (122 [29.6%]), alcohol (120 [29.2%]), or cocaine (46 [11.1%]), and most used visual cues (354 [85.3%]). Together, these studies recruited 19 311 participants, including 13 812 individuals with past or current substance use disorders. Most studies could potentially support biomarker development, including diagnostic (143 [32.7%]), treatment response (141 [32.3%]), severity (84 [19.2%]), prognostic (30 [6.9%]), predictive (25 [5.7%]), monitoring (12 [2.7%]), and susceptibility (2 [0.5%]) biomarkers. A total of 155 interventional studies used FDCR, mostly to investigate pharmacological (67 [43.2%]) or cognitive/behavioral (51 [32.9%]) interventions; 141 studies used FDCR as a response measure, of which 125 (88.7%) reported significant interventional FDCR alterations; and 25 studies used FDCR as an intervention outcome predictor, with 24 (96%) finding significant associations between FDCR markers and treatment outcomes. Conclusions and Relevance: Based on this systematic review and the proposed biomarker development framework, there is a pathway for the development and regulatory qualification of FDCR-based biomarkers of addiction and recovery. Further validation could support the use of FDCR-derived measures, potentially accelerating treatment development and improving diagnostic, prognostic, and predictive clinical judgments.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.986
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.047
GPT teacher head0.339
Teacher spread0.292 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it